image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 0.8228
0.562 %
$ 28.1 M
Market Cap
-82.28
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 23, 2025.

The intrinsic value of one RMTI stock under the worst case scenario is HIDDEN Compared to the current market price of 0.823 USD, Rockwell Medical, Inc. is HIDDEN

This DCF valuation model was last updated on May, 23, 2025.

The intrinsic value of one RMTI stock under the base case scenario is HIDDEN Compared to the current market price of 0.823 USD, Rockwell Medical, Inc. is HIDDEN

This DCF valuation model was last updated on May, 23, 2025.

The intrinsic value of one RMTI stock under the best case scenario is HIDDEN Compared to the current market price of 0.823 USD, Rockwell Medical, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart RMTI

image
$2.4$2.4$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.820252025Feb '25Feb '25Mar '25Mar '25Apr '25Apr '25May '25May '25Jun '25Jun '25Jul '25Jul '25
FINANCIALS
101 M REVENUE
21.38%
608 K OPERATING INCOME
109.12%
-480 K NET INCOME
94.31%
4.2 M OPERATING CASH FLOW
144.65%
-4.87 M INVESTING CASH FLOW
-59.80%
7.35 M FINANCING CASH FLOW
-35.21%
18.9 M REVENUE
-23.32%
-1.36 M OPERATING INCOME
-162.04%
-1.52 M NET INCOME
-100.40%
-3.49 M OPERATING CASH FLOW
-403.12%
-1 K INVESTING CASH FLOW
99.70%
-783 K FINANCING CASH FLOW
-28.04%
Balance Sheet Rockwell Medical, Inc.
image
Current Assets 37 M
Cash & Short-Term Investments 21.6 M
Receivables 8.29 M
Other Current Assets 7.14 M
Non-Current Assets 22.2 M
Long-Term Investments 0
PP&E 10.3 M
Other Non-Current Assets 11.8 M
36.48 %14.00 %12.05 %17.47 %19.99 %Total Assets$59.2m
Current Liabilities 14.1 M
Accounts Payable 2.87 M
Short-Term Debt 0
Other Current Liabilities 11.2 M
Non-Current Liabilities 12.5 M
Long-Term Debt 11.1 M
Other Non-Current Liabilities 1.43 M
10.78 %42.15 %41.70 %5.37 %Total Liabilities$26.6m
EFFICIENCY
Earnings Waterfall Rockwell Medical, Inc.
image
Revenue 101 M
Cost Of Revenue 84 M
Gross Profit 17.5 M
Operating Expenses 16.9 M
Operating Income 608 K
Other Expenses 1.09 M
Net Income -480 K
120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)101m(84m)17m(17m)608k(1m)(480k)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
17.23% GROSS MARGIN
17.23%
0.60% OPERATING MARGIN
0.60%
-0.47% NET MARGIN
-0.47%
-1.47% ROE
-1.47%
-0.81% ROA
-0.81%
1.35% ROIC
1.35%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Rockwell Medical, Inc.
image
5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -480 K
Depreciation & Amortization 2.18 M
Capital Expenditures -1.01 M
Stock-Based Compensation 1.29 M
Change in Working Capital -1.53 M
Others 579 K
Free Cash Flow 3.19 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Rockwell Medical, Inc.
image
Wall Street analysts predict an average 1-year price target for RMTI of $7 , with forecasts ranging from a low of $3 to a high of $11 .
RMTI Lowest Price Target Wall Street Target
3 USD 264.61%
RMTI Average Price Target Wall Street Target
7 USD 750.75%
RMTI Highest Price Target Wall Street Target
11 USD 1236.90%
Price
Max Price Target
Min Price Target
Average Price Target
121210108866442200Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Dec '24Dec '24Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Aug '25Aug '25Oct '25Oct '25Dec '25Dec '25Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Rockwell Medical, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
18 K USD 3
6-9 MONTHS
82 K USD 3
9-12 MONTHS
0 USD 0
Bought
94 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Rockwell Medical, Inc. (RMTI) Q1 2025 Earnings Call Transcript Rockwell Medical, Inc. (NASDAQ:RMTI ) Q1 2025 Earnings Conference Call May 12, 2025 8:00 AM ET Company Participants Heather Hunter - SVP, Chief Corporate Affairs Officer Mark Strobeck - President & CEO Jesse Neri - CFO Conference Call Participants Ram Selvaraju - H.C. Wainwright Jeremy Pearlman - Maxim Group Operator Good morning, and welcome to Rockwell Medical's First Quarter 2025 Results Conference Call and Webcast. seekingalpha.com - 1 month ago
Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates Rockwell Medical (RMTI) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.02 per share a year ago. zacks.com - 1 month ago
Rockwell Medical Announces First Quarter 2025 Results WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical announces financial and operational results for the three months ended March 31, 2025. businesswire.com - 1 month ago
Rockwell Medical to Release First Quarter 2025 Results on Monday, May 12, 2025 WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the first quarter ended March 31, 2025 on Monday, May 12, 2025. businesswire.com - 2 months ago
Rockwell Medical, Inc. (RMTI) Q4 2024 Earnings Call Transcript Rockwell Medical, Inc. (NASDAQ:RMTI ) Q4 2024 Earnings Conference Call March 20, 2025 8:00 AM ET Company Participants Heather Hunter - Senior Vice President, Chief Corporate Affairs Officer Mark Strobeck - President & Chief Executive Officer Tim Chole - Chief Commercial Officer Jesse Neri - Chief Financial Officer Conference Call Participants Brandon Folkes - Rodman & Renshaw Ram Selvaraju - H.C. Wainwright Anthony Vendetti - Maxim Group Operator Good morning, and welcome to Rockwell Medical's Fourth Quarter and Full Year 2024 Results Conference Call and Webcast. seekingalpha.com - 3 months ago
Rockwell Medical (RMTI) Reports Q4 Loss, Tops Revenue Estimates Rockwell Medical (RMTI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.02 per share a year ago. zacks.com - 3 months ago
Rockwell Medical Announces Fourth Quarter and Full-Year 2024 Financial and Operational Results WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical achieves profitability on an adjusted EBITDA basis for the full-year 2024, the first time in the Company's history. businesswire.com - 3 months ago
Rockwell Medical to Exhibit at DialysisTechConneXion42 in Booth# 112 WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will showcase its hemodialysis concentrates portfolio at DialysisTechConneXion42 on April 1-4, 2025 in Las Vegas, NV in Booth #112. businesswire.com - 3 months ago
Rockwell Medical Named 'Great Place to Work' for Third Year in a Row WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical today announced that it has been certified as a Great Place to Work for the third year in a row. businesswire.com - 4 months ago
Rockwell Medical to Release Fourth Quarter and Full-Year 2024 Results on Thursday, March 20, 2025 WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the fourth quarter and full-year ended December 31, 2024 on Thursday, March 20, 2025. businesswire.com - 4 months ago
Rockwell Medical Adds Single-Use Bicarbonate Cartridge to Hemodialysis Concentrates Product Portfolio WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical adds a 510k approved single-use bicarbonate cartridge--in two sizes, 720g and 900g--to its hemodialysis concentrates portfolio. businesswire.com - 5 months ago
Rockwell Medical Enters into a Multi-Year Product Purchase Agreement with the World's Leading Provider of Dialysis Products and Services WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical is the leading supplier of liquid bicarbonate in the United States. businesswire.com - 6 months ago
8. Profile Summary

Rockwell Medical, Inc. RMTI

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 28.1 M
Dividend Yield 0.00%
Description Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Contact 30142 South Wixom road, Wixom, MI, 48393 https://www.rockwellmed.com
IPO Date Jan. 27, 1998
Employees 244
Officers Mr. Nicholas Fanslau Controller & Principal Accounting Officer Ms. Heather H. Hunter Senior Vice President & Chief Corporate Affairs Officer Mr. Jesse Neri Senior Vice President & Chief Financial Officer Mr. Timothy T. Chole Senior Vice President & Chief Commercial Officer Dr. Mark Strobeck Ph.D. President, Chief Executive Officer & Director Ms. Megan C. Timmins Executive Vice President, Chief Legal Officer & Secretary